Moomoo AI 已提取核心訊息
Cybin Inc., a clinical-stage biopharmaceutical company, has filed a Form F-10 with the Securities and Exchange Commission (SEC) on December 29, 2023, for a Registration Statement under the Securities Act of 1933. This filing allows Cybin to offer up to $160,000,000 in securities, which may include common shares, warrants, units, debt securities, and subscription receipts. The securities may be offered from time to time over a 25-month period once the Registration Statement becomes effective. Cybin, based in Ontario, Canada, specializes in developing psychedelic therapeutics for mental health conditions. The company has a broad range of research and development programs, including its proprietary deuterated psilocybin analog program, CYB003, and deuterated dimethyltryptamine program, CYB004. Cybin's financial statements indicate a need for ongoing financing to continue its research and development activities, as the company has not yet achieved profitability and has experienced operating losses since its inception.
Cybin Inc., a clinical-stage biopharmaceutical company, has filed a Form F-10 with the Securities and Exchange Commission (SEC) on December 29, 2023, for a Registration Statement under the Securities Act of 1933. This filing allows Cybin to offer up to $160,000,000 in securities, which may include common shares, warrants, units, debt securities, and subscription receipts. The securities may be offered from time to time over a 25-month period once the Registration Statement becomes effective. Cybin, based in Ontario, Canada, specializes in developing psychedelic therapeutics for mental health conditions. The company has a broad range of research and development programs, including its proprietary deuterated psilocybin analog program, CYB003, and deuterated dimethyltryptamine program, CYB004. Cybin's financial statements indicate a need for ongoing financing to continue its research and development activities, as the company has not yet achieved profitability and has experienced operating losses since its inception.
臨床階段的生物製藥公司Cybin Inc. 已於2023年12月29日向美國證券交易委員會（SEC）提交了F-10表格，要求根據1933年《證券法》提交註冊聲明。該文件允許Cybin發行高達1.6億美元的證券，其中可能包括普通股、認股權證、單位、債務證券和認購收據。註冊聲明生效後，可以在25個月內不時發行這些證券。Cybin總部位於加拿大安大略省，專門開發針對心理健康狀況的迷幻療法。該公司擁有廣泛的研發計劃，包括其專有的氘化迷幻藥類似物項目 CYB003 和氘化二甲基色胺項目 CYB004。Cybin的財務報表表明，由於該公司尚未實現盈利，並且自成立以來一直存在營業虧損，因此需要持續的融資來繼續其研發活動。
臨床階段的生物製藥公司Cybin Inc. 已於2023年12月29日向美國證券交易委員會（SEC）提交了F-10表格，要求根據1933年《證券法》提交註冊聲明。該文件允許Cybin發行高達1.6億美元的證券，其中可能包括普通股、認股權證、單位、債務證券和認購收據。註冊聲明生效後，可以在25個月內不時發行這些證券。Cybin總部位於加拿大安大略省，專門開發針對心理健康狀況的迷幻療法。該公司擁有廣泛的研發計劃，包括其專有的氘化迷幻藥類似物項目 CYB003 和氘化二甲基色胺項目 CYB004。Cybin的財務報表表明，由於該公司尚未實現盈利，並且自成立以來一直存在營業虧損，因此需要持續的融資來繼續其研發活動。
有用
沒用